MediWound (MDWD) vs Satellos Bioscience (MSLE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Satellos Bioscience (MSLE) has outperformed MediWound (MDWD) over the past year, gaining 5.4% versus a loss of 26.7%. Over five years, MDWD leads with a -46.2% price change compared with -48.9% for MSLE. Satellos Bioscience is the larger company by market cap ($166.5 million vs $163.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDWD | MSLE |
|---|---|---|
| Share price | $12.68 | $7.85 |
| Market cap | $163.70M | $166.55M |
| 1-day change | -1.32% | +2.88% |
| YTD return | -30.39% | +29.76% |
| 1-year return | -26.74% | +5.44% |
| 5-year return | -46.17% | -48.93% |
| EPS (TTM) | $-2.17 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.03 | $13.40 |
| 52-week low | $12.52 | $5.30 |
| Distance from 52-week high | -36.69% | -41.40% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +141.88% | +234.39% |
| Average volume | 84.01K | 51.29K |
| Shares outstanding | 12.91M | 21.22M |
| Employees | 121 | 18 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MSLE has outperformed MDWD by 32.2 percentage points over the past year.
About MediWound
MDWD stock →MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Health Care · Medicinal Chemicals and Botanical Products · 121 employees
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
MDWD vs MSLE FAQ
Which is bigger, MediWound or Satellos Bioscience?
Satellos Bioscience (MSLE) is larger, with a market capitalization of $166.55M compared with $163.70M for MediWound (MDWD).
Which stock has performed better over the past year, MDWD or MSLE?
MSLE returned +5.44% over the past 12 months, compared with -26.74% for MDWD (price return, excluding dividends). Past performance does not predict future results.
Are MediWound and Satellos Bioscience in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for MediWound and Biotechnology: Pharmaceutical Preparations for Satellos Bioscience.